Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 307

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 307
---
 collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax      
 Management IV G.P. (2015) Ltd.,                                                                                                                                                                                                                           |

209

| or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share         
 voting and investment power with respect to the shares held by each of the Pontifax Entities. The address of each of the Pontifax Entities is c/o The Pontifax Group, 14 Shenkar Street, Herzelia, Israel. |

| (4) | Consists of 10,000,000 shares of common stock issuable upon conversion of shares of our redeemable convertible                                                                                                                                          
 preferred stock held by TCG Crossover Fund II, L.P. TCG Crossover GP II, LLC is the general partner of TCG Crossover Fund II, L.P. and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the 
 sole managing member of TCG Crossover GP II, LLC and may be deemed to share voting, investment and dispositive power with respect to these securities. Dr. Yu disclaims beneficial ownership over the shares held by TCG Crossover Fund II, L.P.,       
 except to the extent of his pecuniary interest therein. The business address for TCG Crossover GP II LLC, TCG Crossover Fund II, L.P. and Dr. Yu is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301.                                                    |

| (5) | Consists of (i) 1,962,234 shares of common stock beneficially held by Mr. Prensky, (ii) 13,748 shares of                                                                                                                                 
 common stock issuable upon conversion of shares of our redeemable convertible preferred stock beneficially held by Mr. Prensky, (iii) warrants to purchase up to 6,874 shares of common stock beneficially held by Mr. Prensky, and (iv) 
 857,498 shares of common stock issuable upon the exercise of options held by Mr. Prensky that are exercisable within 60 days of June 30, 2025.                                                                                           |

| (6) | Consists of shares of